ATE291619T1 - Dap-2 tumorsupressorgen, durch sie kodierte protein und verwendung besagter gen und protein - Google Patents

Dap-2 tumorsupressorgen, durch sie kodierte protein und verwendung besagter gen und protein

Info

Publication number
ATE291619T1
ATE291619T1 AT95900994T AT95900994T ATE291619T1 AT E291619 T1 ATE291619 T1 AT E291619T1 AT 95900994 T AT95900994 T AT 95900994T AT 95900994 T AT95900994 T AT 95900994T AT E291619 T1 ATE291619 T1 AT E291619T1
Authority
AT
Austria
Prior art keywords
genes
cell death
cytokine
expression
dap
Prior art date
Application number
AT95900994T
Other languages
English (en)
Inventor
Adi Kimchi
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE291619T1 publication Critical patent/ATE291619T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23005—Cathepsin D (3.4.23.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT95900994T 1993-10-12 1994-10-12 Dap-2 tumorsupressorgen, durch sie kodierte protein und verwendung besagter gen und protein ATE291619T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL10725093A IL107250A (en) 1993-10-12 1993-10-12 Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins
PCT/US1994/011598 WO1995010630A1 (en) 1993-10-12 1994-10-12 Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins

Publications (1)

Publication Number Publication Date
ATE291619T1 true ATE291619T1 (de) 2005-04-15

Family

ID=11065332

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95900994T ATE291619T1 (de) 1993-10-12 1994-10-12 Dap-2 tumorsupressorgen, durch sie kodierte protein und verwendung besagter gen und protein

Country Status (8)

Country Link
EP (2) EP1586642A2 (de)
JP (1) JP3791927B2 (de)
AT (1) ATE291619T1 (de)
CA (1) CA2174136A1 (de)
DE (1) DE69434315T2 (de)
ES (1) ES2240971T3 (de)
IL (1) IL107250A (de)
WO (1) WO1995010630A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6160106A (en) * 1993-10-12 2000-12-12 Yeda Research & Development Co., Ltd. Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
CA2262696A1 (en) 1996-08-02 1998-02-12 Dana-Farber Cancer Institute Bcl-xy, a novel bcl-x isoform, and uses related thereto
US5776759A (en) * 1996-09-26 1998-07-07 Incyte Pharmaceuticals, Inc. Two novel human cathepsin proteins
ATE393227T1 (de) * 1996-11-20 2008-05-15 Oklahoma Med Res Found Klonierung und charakterisierung von napsin, einer aspartat-protease
GB9701684D0 (en) * 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
KR20010086587A (ko) 1998-02-27 2001-09-13 데이비드 이. 프랭크하우저 유전자 요법에 의한 염증성 세포의 자기-조절된 고사
JP2002506651A (ja) * 1998-03-16 2002-03-05 イントロジェン・セラピューティクス，インコーポレイテッド 多重遺伝子ベクター
WO1999066030A1 (en) * 1998-06-15 1999-12-23 Yeda Research And Development Company Ltd. Dap-kinase related protein
US7026148B1 (en) 1998-06-15 2006-04-11 Yeda Research And Development Co., Ltd. DAP-kinase related protein
US6255293B1 (en) 1998-07-24 2001-07-03 Yeda Research And Development Co., Ltd. Prevention of metastasis with 5-aza-2′-deoxycytidine
JP2003516122A (ja) * 1999-10-13 2003-05-13 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ｄａｐキナーゼのショートセグメント
AU2002217962A1 (en) * 2000-11-17 2002-05-27 The Burnham Institute Death domain proteins
US6965023B2 (en) 2000-11-17 2005-11-15 The Burnham Institute Death domain proteins
JPWO2003083101A1 (ja) * 2002-03-29 2005-08-04 三菱ウェルファーマ株式会社 Ｄａｐキナーゼの結晶、それを用いたｄａｐキナーゼをターゲットとする薬物候補分子のスクリーニング方法及びそれにより得られる医薬
EP2545170A1 (de) 2010-03-11 2013-01-16 Yeda Research And Development Co. Ltd. Zelltod-assoziierte protein-1-varianten und verwendung zur modulation von autophagie
US9149523B2 (en) 2010-12-15 2015-10-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer and neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542096A (en) * 1983-02-25 1985-09-17 President And Fellows Of Harvard College Detecting rearranged human c-myc DNA fragments associated with oncogenes
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US5015570A (en) * 1988-05-13 1991-05-14 Molecular Therapeutics, Inc. Molecular diagnosis of Alzheimer Disease
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
GB9122051D0 (en) * 1991-10-17 1991-11-27 Univ Nottingham Medicines

Also Published As

Publication number Publication date
DE69434315D1 (de) 2005-04-28
DE69434315T2 (de) 2006-03-30
EP0804613B1 (de) 2005-03-23
WO1995010630A1 (en) 1995-04-20
ES2240971T3 (es) 2005-10-16
IL107250A0 (en) 1994-01-25
EP0804613A4 (de) 1999-07-14
JPH09505992A (ja) 1997-06-17
CA2174136A1 (en) 1995-04-20
JP3791927B2 (ja) 2006-06-28
IL107250A (en) 2001-08-08
EP0804613A1 (de) 1997-11-05
EP1586642A2 (de) 2005-10-19

Similar Documents

Publication Publication Date Title
ATE291619T1 (de) Dap-2 tumorsupressorgen, durch sie kodierte protein und verwendung besagter gen und protein
WO1995031559A3 (en) Methods of inducing gene expression by ionizing radiation
DE69333815D1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
MX9705039A (es) Genes y proteinas de muerte celular programada.
ATE335831T1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
HK1024714A1 (en) Dumbbell expression constructs for gene therapy
DE69433661D1 (de) Genetische modifikation von neuralen stammzellen
PL352332A1 (en) Expression and export of interferon-alpha proteins as fc fusion proteins
FI97809B (fi) Rekombinantti-DNA-molekyyli, joka koodaa kudosperäisen plasminogeenin aktivaattorin (TPA) analogia
Maki et al. The polymerase subunit of DNA polymerase III of Escherichia coli. I. Amplification of the dnaE gene product and polymerase activity of the alpha subunit.
DE69332525D1 (de) Behandlung von Tumorerkrankungen mit modifiziertem HSV
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
NZ234453A (en) Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
HU9300397D0 (en) Method for modifying tropism of micor-organisms to cells, tissues and host organisms recombinant micro-organisms obtained by this way and their application in human and veterinary medicine
NZ242124A (en) Dna encoding an enzyme having arabinan-degrading activity
Echols et al. In vitro repression of phage lambda DNA transcription by a partially purified repressor from lysogenic cells.
AP9901469A0 (en) Protein kinases and uses thereof.
ATE221124T1 (de) Kombinationsvektoren zum austragen von genmaterial
WO1995027070A1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
Suhasini et al. Onconase action on tRNALys3, the primer for HIV-1 reverse transcription
ATE325874T1 (de) Cd154 varianten und deren verwendung
WO2000030590A3 (en) Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2
Raab et al. Cell free synthesis of bacteriophage lambda replication proteins
Sheinin et al. Some properties of chromatin synthesized by mouse-L-cells temperature-sensitive in DNA replication.
Prigent et al. Identification of DNA ligase I related polypeptides in three different human cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties